Beam Therapeutics (BEAM) Operating Margin (2019 - 2025)
Beam Therapeutics (BEAM) has disclosed Operating Margin for 7 consecutive years, with 306.24% as the latest value for Q4 2025.
- Quarterly Operating Margin rose 63896.0% to 306.24% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.02% through Dec 2025, up 64223.0% year-over-year, with the annual reading at 12.02% for FY2025, 64223.0% up from the prior year.
- Operating Margin for Q4 2025 was 306.24% at Beam Therapeutics, up from 1307.6% in the prior quarter.
- The five-year high for Operating Margin was 306.24% in Q4 2025, with the low at 3339550.0% in Q1 2021.
- Average Operating Margin over 5 years is 217150.8%, with a median of 688.06% recorded in 2024.
- The sharpest move saw Operating Margin crashed -286696667bps in 2021, then soared 333864600bps in 2022.
- Over 5 years, Operating Margin stood at 124.31% in 2021, then crashed by -257bps to 444.1% in 2022, then soared by 109bps to 42.02% in 2023, then crashed by -892bps to 332.71% in 2024, then soared by 192bps to 306.24% in 2025.
- According to Business Quant data, Operating Margin over the past three periods came in at 306.24%, 1307.6%, and 1419.22% for Q4 2025, Q3 2025, and Q2 2025 respectively.